TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER).
Travasol 2.75% in Dextrose 25% is a parenteral nutrition solution providing amino acids and carbohydrates. The amino acids serve as substrates for protein synthesis, while dextrose provides a source of calories and spares protein catabolism. It does not have a direct pharmacological target but supports metabolic functions.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle pathways; dextrose is metabolized via glycolysis and the citric acid cycle. |
| Excretion | Renal: 100% as amino acids and dextrose metabolites; negligible biliary/fecal elimination. |
| Half-life | Not applicable as a single entity; amino acids have variable half-lives (minutes to hours), dextrose has a half-life of 1.5-2 hours in normoglycemic patients; clinical context: continuous infusion maintains steady state. |
| Protein binding | < 10% bound; primarily albumin for tryptophan and tyrosine; most amino acids unbound. |
| Volume of Distribution | 0.5-0.8 L/kg for amino acids (total body water); dextrose Vd ~ 0.2 L/kg; clinical meaning: rapid distribution into lean body mass. |
| Bioavailability | Intravenous: 100%; not administered via other routes. |
| Onset of Action | Intravenous: immediate (minutes) for caloric provision and nitrogen sparing; clinical effect (protein synthesis) within hours to days. |
| Duration of Action | Duration depends on infusion rate; continuous IV infusion provides sustained effect; post-infusion: metabolic effects persist for several hours. |
| Molecular Weight | Amino acids: ~75-204 Da (individual); Dextrose: 180.16 Da |
Intravenous administration only. Typical adult dose is 1 to 2 L per day, infused at a rate of 100 to 200 mL per hour, adjusted based on metabolic and fluid needs. Contains 2.75% amino acids and 25% dextrose.
| Dosage form | INJECTABLE |
| Renal impairment | In acute kidney injury or chronic kidney disease, dose reduction is typically not required for amino acid component; however, adjust fluid volume and dextrose content based on fluid and glucose tolerance. For GFR <30 mL/min/1.73 m², consider reducing total fluid volume to avoid overload and monitor electrolytes. In dialysis patients, administer during dialysis or adjust for fluid removal. |
| Liver impairment | In hepatic impairment, use with caution. For Child-Pugh class A, no adjustment; class B, consider reducing total protein intake (0.8-1.0 g/kg/day) and monitor ammonia; class C, avoid or use only if benefits outweigh risks, with dose adjustment based on encephalopathy status and close monitoring of amino acid profile. |
| Pediatric use | Weight-based dosing: Amino acid component 1-3 g/kg/day (0.1-0.3 g/kg/hour) depending on age and clinical status; dextrose component 5-20 mg/kg/min. Total fluid: For neonates, start at 60-80 mL/kg/day, increase as tolerated. For older children, 100-150 mL/kg/day. Adjust based on metabolic demands and clinical response. |
| Geriatric use | Elderly patients often require lower fluid volumes due to reduced cardiac and renal reserve. Start at 500-1000 mL per day, infuse at 50-100 mL/hour. Monitor glucose and electrolytes closely, as dextrose load may cause hyperglycemia. Adjust based on renal function (eGFR) and comorbidities. |
| 1st trimester | Amino acid/dextrose combinations are generally used only when maternal nutrition is critical. No adequate studies in pregnant women. Use only if clearly needed. |
| 2nd trimester | Same as t1. Monitor maternal glucose and electrolytes. Potential risks from hyperglycemia or electrolyte imbalances. |
| 3rd trimester | Same as t1. May affect fetal growth if maternal metabolic status is uncontrolled. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER).
| Placental transfer | Amino acids and dextrose cross the placenta by passive diffusion and active transport. Transfer is physiological and required for fetal growth. |
| Breastfeeding | Amino acids and dextrose are normal constituents of breast milk. Intravenous infusion should not affect lactation. Use only if compatible with maternal nutritional needs. |
| Lactation Rating | L1 |
| Teratogenic Risk | Travasol 2.75% in Dextrose 25% is not a drug but a nutrient solution. No fetal risks are expected from amino acids and dextrose at therapeutic doses. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose is poorly controlled. No specific teratogenicity in any trimester. |
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes, and fluid balance during infusion. Fetal monitoring per standard obstetric care, particularly if maternal glucose is elevated. |
| Fertility Effects | No known effects on fertility from amino acids or dextrose at standard parenteral nutrition doses. |
■ FDA Black Box Warning
None specified by FDA for this specific formulation.
| Serious Effects |
Hypersensitivity to any componentSevere electrolyte imbalancesSevere metabolic disorders (e.g., maple syrup urine disease)Anuria or oliguriaPulmonary edemaGalactosemia (dextrose component)
| Precautions | Risk of infection from catheter-related bloodstream infections, Fluid and electrolyte imbalances, Hyperglycemia or hypoglycemia, Hepatic steatosis or cholestasis, Metabolic acidosis or alkalosis, Aluminum toxicity in neonates or renal impairment, Refeeding syndrome in severely malnourished patients, Monitor serum electrolytes, glucose, liver function, and triglycerides |
| Food/Dietary | No direct food interactions; however, dietary intake should be adjusted to avoid overfeeding or electrolyte imbalances. Oral intake, if allowed, should be coordinated with IV nutrition. |
| Clinical Pearls | TRAVASOL 2.75% IN DEXTROSE 25% is a high-osmolality parenteral nutrition solution (approx. 1500 mOsm/L) requiring central venous administration to avoid thrombophlebitis. Monitor serum electrolytes, glucose, and liver function tests frequently. Avoid sudden discontinuation to prevent rebound hypoglycemia. Contraindicated in patients with severe hyperglycemia, hyperosmolar coma, or galactosemia. |
| Patient Advice | This solution is given through a central vein to prevent vein irritation. · Report any signs of infection at the IV site (redness, swelling, pain) or difficulty breathing. · Blood tests will be done regularly to check your sugar, salt levels, and liver function. · Do not stop the infusion suddenly without medical advice to avoid low blood sugar. · Inform your doctor if you have diabetes or kidney disease. |
Loading safety data…